A271 THE MODULATION OF INTESTINAL INFLAMMATION BY PARABACTEROIDES GOLDSTEINII IN EXPERIMENTAL MURINE COLITIS. (7th March 2023)
- Record Type:
- Journal Article
- Title:
- A271 THE MODULATION OF INTESTINAL INFLAMMATION BY PARABACTEROIDES GOLDSTEINII IN EXPERIMENTAL MURINE COLITIS. (7th March 2023)
- Main Title:
- A271 THE MODULATION OF INTESTINAL INFLAMMATION BY PARABACTEROIDES GOLDSTEINII IN EXPERIMENTAL MURINE COLITIS
- Authors:
- Gerkins, C
Oliero, M
Hajjar, R
Vennin Rendos, H
Fragoso, G
Calvé, A
Diop, K
Routy, B
Santos, M M - Abstract:
- Abstract: Background: Inflammatory bowel diseases (IBDs), comprised mainly of Crohn's disease and ulcerative colitis, are characterized by chronic and relapsing intestinal inflammation. Though the etiology of IBDs is not entirely understood, it is thought that an imbalance of the gut microbiota is one contributing factor, making it a potential target for the treatment of IBDs. Purpose: This study aims to examine how the potential probiotic Parabacteroides goldsteinii modulates intestinal inflammation in the context of experimental colitis. Method: Wild type C57BL/6 mice were divided into three groups. One group was given phosphate-buffered saline (PBS) via oral gavage without any further treatment. The second group was treated with 1% dextran sodium sulfate (DSS) for twelve days induce colitis and given PBS every three days. Finally, the third group was also treated with 1% DSS for twelve days and given P. goldsteinii via oral gavage every three days. Weight loss, stool consistency, and intestinal bleeding were monitored and were used to calculate the Disease Activity Index (DAI) daily. Postmortem, colon length was measured, and inflammation score was evaluated on hematoxylin and eosin-stained samples of the colon and spleen. Finally, inflammatory cytokine levels were measured in the colon tissue and the serum by multiplex assay. Result(s): Colonization was confirmed at day three after gavage by real-time PCR. Preliminary results show that DSS-treated mice lost significantlyAbstract: Background: Inflammatory bowel diseases (IBDs), comprised mainly of Crohn's disease and ulcerative colitis, are characterized by chronic and relapsing intestinal inflammation. Though the etiology of IBDs is not entirely understood, it is thought that an imbalance of the gut microbiota is one contributing factor, making it a potential target for the treatment of IBDs. Purpose: This study aims to examine how the potential probiotic Parabacteroides goldsteinii modulates intestinal inflammation in the context of experimental colitis. Method: Wild type C57BL/6 mice were divided into three groups. One group was given phosphate-buffered saline (PBS) via oral gavage without any further treatment. The second group was treated with 1% dextran sodium sulfate (DSS) for twelve days induce colitis and given PBS every three days. Finally, the third group was also treated with 1% DSS for twelve days and given P. goldsteinii via oral gavage every three days. Weight loss, stool consistency, and intestinal bleeding were monitored and were used to calculate the Disease Activity Index (DAI) daily. Postmortem, colon length was measured, and inflammation score was evaluated on hematoxylin and eosin-stained samples of the colon and spleen. Finally, inflammatory cytokine levels were measured in the colon tissue and the serum by multiplex assay. Result(s): Colonization was confirmed at day three after gavage by real-time PCR. Preliminary results show that DSS-treated mice lost significantly more weight by day twelve than mice colonized with P. goldsteinii . Additionally, on days eight and twelve, mice colonized with P. goldsteinii had significantly lower DAI scores than mice that received only PBS. Finally, mice colonized with P. goldsteinii had significantly longer colons than those that received only PBS. Conclusion(s): The preliminary data indicates that mice colonized with P. goldsteinii had less severe symptoms of colitis than mice only given PBS. This suggests that P. goldsteinii may attenuate inflammation in mice treated with DSS. Please acknowledge all funding agencies by checking the applicable boxes below: CIHR Disclosure of Interest: None Declared … (more)
- Is Part Of:
- Journal of the Canadian Association of Gastroenterology. Volume 6(2023)Supplement 1
- Journal:
- Journal of the Canadian Association of Gastroenterology
- Issue:
- Volume 6(2023)Supplement 1
- Issue Display:
- Volume 6, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 6
- Issue:
- 1
- Issue Sort Value:
- 2023-0006-0001-0000
- Page Start:
- 86
- Page End:
- 87
- Publication Date:
- 2023-03-07
- Subjects:
- Gastroenterology -- Periodicals
616.33005 - Journal URLs:
- https://academic.oup.com/jcag ↗
http://www.oxfordjournals.org/ ↗ - DOI:
- 10.1093/jcag/gwac036.271 ↗
- Languages:
- English
- ISSNs:
- 2515-2084
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26873.xml